Lv1
94 积分 2022-03-04 加入
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial
5天前
已完结
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
1个月前
已完结
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
1个月前
已完结
Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer: A Randomized Clinical Trial
1个月前
已完结
Pan-cancer analysis of RNA expression signatures associated with cancer tissue architecture
4个月前
已完结
Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer
6个月前
已完结
Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery
9个月前
已完结
Topoisomerase I inhibitors: camptothecins and beyond
9个月前
已完结
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
11个月前
已完结
Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial
11个月前
已完结
皖公网安备34019202002308
